Compare Bristol-Myers Squibb Co (BMY) vs Intuit Inc. (INTU) Price & Performance

Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.

BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.

Intuit (INTU) trades at $289.73, up 5.37% in the last session, with a bullish technical signal and strong support at $284. The company reported robust earnings, beating estimates for Q3 2025, Q4 2025, and Q1 2026, with revenue growth from $18.83B in 2025 to a projected $20.9B in 2026. Profit margins improved to 21.91% net income margin, while valuation ratios like P/E of 17.23 and P/S of 3.78 indicate reasonable pricing. However, recent news highlights a 20% stock drop and securities fraud investigations, adding volatility.

Outlook remains positive due to consistent earnings beats and AI-driven growth, but risks include legal scrutiny and competitive pressures. Analysts maintain a 71.11% buy rating with a $422.88 consensus target, suggesting potential upside if the company navigates current challenges effectively.